Onkologie. 2021:15(6):277-283 | DOI: 10.36290/xon.2021.052

Identification and management of early-stage lung cancer

Daniel Krejčí, Norbert Pauk
Klinika pneumologie, 3. LF UK a Fakultní nemocnice Na Bulovce, Praha

Lung cancer is known as aggressive disease with poor prognosis which correlates with the baseline tumour clinical stage. Screening programs aim to identify lung cancer in early-stages to increase survival. Surgery is preferred treatment modality, but radiotherapy can be equal option, too. In some patients we administer the adjuvant or induction treatment like chemotherapy. Immunotherapy and targeted therapy have also big potential in early setting according to the actual data. This article reviews identification and treatment possibilities of the early-stage non-small cell lung cancer.

Keywords: early-stage, lung cancer.

Published: November 24, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krejčí D, Pauk N. Identification and management of early-stage lung cancer. Onkologie. 2021;15(6):277-283. doi: 10.36290/xon.2021.052.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. O'Sullivan B, et al. The TNM classification of malignant tumours-towards common understanding and reasonable expectations. The Lancet Oncology 2017; 18(7): p. 849-851. Go to original source... Go to PubMed...
    2. Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2015; 10(7): p. 990-1003. Go to original source... Go to PubMed...
    3. Howington JA, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(5 Suppl): p. e278S-e313S. Go to original source...
    4. van den Berg LL, et al. Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC. J Thorac Oncol 2015; 10(5): p. 826-831. Go to original source... Go to PubMed...
    5. Timmerman R, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. Jama 2010; 303(11): p. 1070-6. Go to original source... Go to PubMed...
    6. Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021. Go to original source... Go to PubMed...
    7. Dušek L, Mužík J, Kubásek M, Koptíková J, Žaloudík J, Vyzula R. Epidemiologie zhoubných nádorů v České republice. Multimediální podpora výuky klinických a zdravotnických oborů: Portál Lékařské fakulty Masarykovy univerzity [online] [cit. 06. 04. 2021]]; Available from: https://portal.med.muni.cz/clanek-583-epidemiologie-zhoubnych-nadoru-v-ceske-republice.html.
    8. Jassem J. Lung cancer: a preventable disease. Transl Lung Cancer Res, 2019; 8(Suppl 1): p. S1-S2. Go to original source... Go to PubMed...
    9. Tomásek L, et al. Study of lung cancer and residential radon in the Czech Republic. Cent Eur J Public Health 2001; 9(3): 150-3.
    10. Venclíček O. Zevní rizikové faktory vzniku karcinomu plic u kuřáků. Onkologie 2020; 14(1): 45-46. Go to original source...
    11. Wilson JMG, Jungner G. Geneva: World Health Organization; 1968. Principles and practice of screening for disease.
    12. Sharma D, Newman TG, Aronow WS. Lung cancer screening: history, current perspectives, and future directions. Arch Med Sci 2015; 11(5): 1033-43.
    13. Brett GZ. The value of lung cancer detection by six-monthly chest radiographs. Thorax 1968; 23(4): 414-20. Go to original source... Go to PubMed...
    14. Berlin NI, et al. The National Cancer Institute Cooperative Early Lung Cancer Detection Program. Results of the initial screen (prevalence). Early lung cancer detection: Introduction. Am Rev Respir Dis 1984; 130(4): p. 545-9.
    15. Melamed MR, et al. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 1984; 86(1): p. 44-53. Go to original source... Go to PubMed...
    16. Xu GY, et al. Glutamate-induced losses of oligodendrocytes and neurons and activation of caspase-3 in the rat spinal cord. Neuroscience 2008; 153(4): p. 1034-1047. Go to original source... Go to PubMed...
    17. Kaneko M, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996; 201(3): p. 798-802. Go to original source... Go to PubMed...
    18. Sone S, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998; 351(9111): p. 1242-5. Go to original source... Go to PubMed...
    19. Aberle DR, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365(5): p. 395-409. Go to original source... Go to PubMed...
    20. De Koning H, et al. PL02.05 Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial. Journal of Thoracic Oncology 2018; 13(10): p. S185. Go to original source...
    21. Bueno J, Landeras L, Chung JH. Updated Fleischner Society Guidelines for Managing Incidental Pulmonary Nodules: Common Questions and Challenging Scenarios. Radiographics 2018; 38(5): p. 1337-1350. Go to original source... Go to PubMed...
    22. Gould MK, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(5 Suppl): p. e93S-e120S. Go to original source...
    23. Callister ME, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax 2015; 70 Suppl 2: p. ii1-ii54. Go to original source... Go to PubMed...
    24. Tanner NT, et al. Physician Assessment of Pretest Probability of Malignancy and Adherence With Guidelines for Pulmonary Nodule Evaluation. Chest 2017; 152(2): p. 263-270. Go to original source... Go to PubMed...
    25. Graham EA, Singer JJ. Landmark article Oct 28, 1933. Successful removal of an entire lung for carcinoma of the bronchus. Jama 1984; 251(2): p. 257-60. Go to original source... Go to PubMed...
    26. Deslauriers J, et al. Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences. Ann Thorac Surg2004; 77(4): p. 1152-6; discussion 1156. Go to original source... Go to PubMed...
    27. Deslauriers J, et al. Long-term clinical and functional results of sleeve lobectomy for primary lung cancer. J Thorac Cardiovasc Surg 1986; 92(5): p. 871-9. Go to original source...
    28. Ferguson MK, Lehman AG. Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Ann Thorac Surg 2003; 76(6): p. 1782-8. Go to original source... Go to PubMed...
    29. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60(3): p. 615-22; discussion 622-3. Go to original source... Go to PubMed...
    30. Allen MS, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg 2006; 81(3): p. 1013-9; discussion 1019-20. Go to original source... Go to PubMed...
    31. Whitson BA, et al. Survival after lobectomy versus segmentectomy for stage I non-small cell lung cancer: a population-based analysis. Ann Thorac Surg 2011; 92(6): p. 1943-50. Go to original source... Go to PubMed...
    32. Fan J, et al. Sublobectomy versus lobectomy for stage I non-small-cell lung cancer, a meta-analysis of published studies. Ann Surg Oncol 2012; 19(2): p. 661-8. Go to original source... Go to PubMed...
    33. Koike T, et al. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg 2013; 146(2): 372-378. Go to original source... Go to PubMed...
    34. El-Sherif A, et al. Margin and local recurrence after sublobar resection of non-small cell lung cancer. Ann Surg Oncol 2007; 14(8): 2400-2405. Go to original source... Go to PubMed...
    35. Lim E, et al. Guidelines on the radical management of patients with lung cancer. Thorax 2010; 65 Suppl 3: p. iii1-27. Go to original source... Go to PubMed...
    36. Schuchert MJ, et al. Oncologic outcomes after surgical resection of subcentimeter non-small cell lung cancer. Ann Thorac Surg 2011; 91(6): 1681-7; discussion 1687-8. Go to original source... Go to PubMed...
    37. Jeon HW, et al. Sublobar resection versus lobectomy in solid-type, clinical stage IA, non-small cell lung cancer. World J Surg Oncol 2014; 12: 215. Go to original source... Go to PubMed...
    38. Blasberg JD, Pass HI, Donington JS. Sublobar resection: a movement from the Lung Cancer Study Group. J Thorac Oncol 2010; 5(10): 1583-93. Go to PubMed...
    39. Nakamura K, et al. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol 2010; 40(3): 271-4. Go to original source... Go to PubMed...
    40. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 1978; 76(6): p. 832-9. Go to original source...
    41. Rami-Porta R, Wittekind C, Goldstraw P. Complete resection in lung cancer surgery: proposed definition. Lung Cancer 2005; 49(1): 25-33. Go to original source... Go to PubMed...
    42. Darling GE, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011; 141(3): 662-70. Go to original source... Go to PubMed...
    43. Graham AN, et al. Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 1999; 117(2): 246-51. Go to original source... Go to PubMed...
    44. Kung BT, Yong TK, Tong CM. The Pearl of FDG PET/CT in Preoperative Assessment of Patients with Potentially Operable Non-Small-Cell Lung Cancer and its Clinical Impact. World J Nucl Med 2017; 16(1): 21-25. Go to original source... Go to PubMed...
    45. Farjah F, et al. A prediction model for pathologic N2 disease in lung cancer patients with a negative mediastinum by positron emission tomography. J Thorac Oncol 2013; 8(9): 1170-80. Go to original source... Go to PubMed...
    46. Suh YJ, et al. Utility of FDG PET/CT for Preoperative Staging of Non-Small Cell Lung Cancers Manifesting as Subsolid Nodules With a Solid Portion of 3 cm or Smaller. AJR Am J Roentgenol 2020; 214(3): 514-523. Go to original source... Go to PubMed...
    47. Sehgal IS, et al. Role of EBUS TBNA in Staging of Lung Cancer: A Clinician's Perspective. J Cytol 2019; 36(1): 61-64. Go to original source... Go to PubMed...
    48. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. Bmj 1995; 311(7010): 899-909. Go to PubMed...
    49. Arriagada R, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350(4): 351-60. Go to original source... Go to PubMed...
    50. Pignon JP, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26(21): 3552-3559. Go to original source... Go to PubMed...
    51. Indini A, et al. Novel treatment strategies for early-stage lung cancer: the oncologist's perspective. J Thorac Dis 2020; 12(6): 3390-3398. Go to original source... Go to PubMed...
    52. Postmus PE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28(suppl. 4): iv1-iv21. Go to original source... Go to PubMed...
    53. Strauss GM, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26(31): 5043-51. Go to original source... Go to PubMed...
    54. Felip E, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 2010; 28(19): 3138-3145. Go to original source... Go to PubMed...
    55. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014; 383(9928): 1561-1571.
    56. Anichini A, et al. Immune Escape Mechanisms in Non Small Cell Lung Cancer. Cancers (Basel), 2020; 12(12). Go to original source... Go to PubMed...
    57. Doroshow DB, et al. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clin Cancer Res 2019; 25(15): 4592-4602. Go to original source... Go to PubMed...
    58. Chambers CA, et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19: 565-94.. Go to original source... Go to PubMed...
    59. Garelli E, et al. Abscopal effect in lung cancer: three case reports and a concise review. Immunotherapy 2019; 11(17): 1445-1461. Go to original source... Go to PubMed...
    60. Travis WD, et al. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. J Thorac Oncol 2020; 15(5): 709-740. Go to original source... Go to PubMed...
    61. Camidge DR, et al. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. J Thorac Oncol 2019; 14(7): p. 1233-1243. Go to original source... Go to PubMed...
    62. Soria JC, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine 2017; 378(2): 113-125. Go to original source... Go to PubMed...
    63. Zhong WZ, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol 2018; 19(1): 139-148. Go to original source... Go to PubMed...
    64. Zhong WZ, et al. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol 2021; 39(7): 713-722. Go to original source... Go to PubMed...
    65. Wu YL, et al. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. Clin Lung Cancer 2018; 19(4): e533-e536. Go to original source... Go to PubMed...
    66. Herbst RS, Tsuboi M, John T, et al. Osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation positive NSCLC after complete tumor resection: ADAURA. ASCO20 Virtual Scientific Program. Abstract LBA5: Presented in premeeting press briefing on May 26, 2020. Go to original source...
    67. Govindan R, et al. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clin Cancer Res 2015; 21(24): 5439-44. Go to original source... Go to PubMed...
    68. Sands J, et al. ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC. Journal of Clinical Oncology 2020; 38(15_suppl): p. TPS9077-TPS9077. Go to original source...
    69. Potters L, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010; 76(2): 326-32. Go to original source... Go to PubMed...
    70. De Ruysscher D, Nakagawa K, Asamura H. Surgical and nonsurgical approaches to small-size nonsmall cell lung cancer. European Respiratory Journal 2014; 44(2): 483-494. Go to original source... Go to PubMed...
    71. Soldà F, et al. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol 2013; 109(1): 1-7. Go to original source... Go to PubMed...
    72. Widder J, et al. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer. Int J Radiat Oncol Biol Phys 2011; 81(4): e291-297. Go to original source... Go to PubMed...
    73. Adebahr S, et al. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 2015; 88(1051): 20150036. Go to original source... Go to PubMed...
    74. Robinson C, et al. P1.18-12 PACIFIC-4/RTOG 3515: Phase III Study of Durvalumab Following SBRT for Unresected Stage I/II, Lymph-Node Negative NSCLC. Journal of Thoracic Oncology 2019; 14(Suppl. 10): S630-S631. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.